Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 5, 2009, Pages 778-783

  Park, H W ^b,c   Yang, M S ^b,c   Park, C S ^b   Kim, T B ^b   Moon, H B ^b   Min, K U ^b,c   Kim, Y Y ^b,c   Cho, S H ^a,b,c  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

2 adrenorecptor; Anticholinergic agent; Asthma; Muscarinic receptor; Pharmacogenetics

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE; CORTICOSTEROID; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PREDNISOLONE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ALLELES; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 63849193838     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01876.x     Document Type: Article

References (42)

1. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984 311 : 421 425.
2. Ruffin RE, Fitzgerald JD, Rebuck AS. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. J Allergy Clin Immunol 1977 59 : 136 141.
3. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006 533 : 36 39.
4. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996 154 : 876 880.
5. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001 10 : 733 740.
6. Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007 52 : 833 851.
7. Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005 171 : 1096 1102.
8. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007 30 : 653 661.
9. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008 102 : 50 56.
10. Migita O, Noguchi E, Jian Z, Shibasaki M, Migita T, Ichikawa K et al. ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta-analysis. Int Arch Allergy Immunol 2004 134 : 150 157.
11. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005 115 : 963 972.
12. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D et al. Systematic review and metaanalysis of the association between b2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005 162 : 201 211.
13. Umeda N, Yoshikawa T, Kanazawa H, Hirata K, Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology 2008 13 : 346 352.
14. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2005 2 : 305 310.
15. McGraw DW, Elwing JM, Fogel KM, Wang WC, Glinka CB, Mihlbachler KA et al. Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. J Clin Invest 2007 117 : 1391 1398.
16. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 2003 112 : 619 626.
17. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report. Can Med Assoc J 1999 161 : S1 S62.
18. Ungar WJ, Champman KR, Santos MT. Assessment of a medication-based asthma index for population research. Am J Respir Crit Care Med 2002 165 : 190 194.
19. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 23 : 932 946.
20. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004 292 : 367 376.
21. Gillissen A. Patients' adherence in asthma. J Physiol Pharmacol 2007 58 (Suppl. 5 233 241.
22. Park HW, Lee JE, Shin ES, Lee JY, Bahn JW, Oh HB et al. Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population. J Allergy Clin Immunol 2006 117 : 774 779.
23. Taylor DR. Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy Immunol 2006 31 : 247 258.
24. Bhatnagar P, Guleria R, Kukreti R. Pharmacogenomics of beta2-agonist: key focus on signaling pathways. Pharmacogenomics 2006 7 : 919 933.
25. Park HW, Shin ES, Lee JE, Kim SH, Kim SS, Chang YS et al. Association between genetic variations in prostaglandin E2 receptor subtype EP3 gene (Ptger3) and asthma in the Korean population. Clin Exp Allergy 2007 37 : 1609 1615.
26. American Thoracic Society. Proceedings of the ATS Workshop on Refractory Asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000 162 : 2341 2351.
27. Molfino NA, Slutsky AS, Julià-Serdà G, Hoffstein V, Szalai JP, Chapman KR et al. Assessment of airway tone in asthma. Comparison between double lung transplant patients and healthy subjects. Am Rev Respir Dis 1993 148 : 1238 1243.
28. Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest 1989 96 : 1285 1291.
29. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 1992 72 : 699 729.
30. Kanazawa H, Kawaguchi T, Shoji S, Fujii T, Kudoh S, Hirata K et al. Synergistic effect of nitric oxide and vasoactive intestinal peptide on bronchoprotection against histamine in anesthetized guinea pigs. Am J Respir Crit Care Med 1997 155 : 747 750.
31. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006 6 : 311 326.
32. Hall IP. Pharmacogenetics of asthma. Chest 2006 130 : 1873 1878.
33. Hall IP, Sayers I. Pharmacogenetics and asthma: false hope or new dawn? Eur Respir J 2007 29 : 1239 1245.
34. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004 364 : 1505 1512.
35. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006 61 : 940 944.
36. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH et al. Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006 118 : 809 816.
37. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long-acting β2-agonist therapy. Lancet 2007 370 : 2118 2125.
38. Taylor DR, Hall IP. ADRB2 polymorphisms and beta2 agonists. Lancet 2007 370 : 2075 2076.
39. Yang IA, Ng T, Molenaar P, Fong KM. Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design. Clin Exp Pharmacol Physiol 2007 34 : 1029 1036.
40. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005 366 : 1315 1323.
41. Healy DG. Case-control studies in the genomic era: a clinician's guide. Lancet Neurol 2006 5 : 701 707.
42. Lima JJ, Holbrook JT, Wang J, Sylvester JE, Blake KV, Blumenthal MN et al. The C523A beta2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. J Asthma 2006 43 : 185 191.